Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 2/20 | 0.54 |
| ▸ | NQO2 | P16083 | 12/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 3/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433306 | 0.87 | PRMT1 (0.56) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL5489885 | 0.87 | PRMT1 (0.59) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL5492386 | 0.82 | PRMT1 (0.51) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| Pafuramidine SCHEMBL5143735 | 0.79 | NQO2 (0.57) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL3504227 | 0.79 | NQO2 (0.57) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL5491216 | 0.77 | PRMT1 (0.59) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL5493324 | 0.75 | NQO2 (0.45) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL14433308 | 0.74 | PRMT1 (0.52) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| SCHEMBL5492376 | 0.74 | PRMT1 (0.55) | PRMT1NQO2ALDH1A1TOP1HPGD | |
| Pafuramidine SCHEMBL14599558 | 0.73 | NQO2 (0.53) | PRMT1NQO2ALDH1A1TOP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256203-B2 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1565458-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | BOYKIN DAVID W (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004050018-A2 | DICATIONIC 2,5-DIARYLFURAN AZA-ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122015-A1 | Dicationic 2,5-diarylfuran aza-analogs as anti-protozoan agents | NR0B1, NR2C2, DECR1 | PRMT1 1323/4885NQO2 982/4885ALDH1A1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.